ひと心筋細胞外マトリックスの in VitroとIn Vivo応用のハイドロゲルを自己組織化に向けての処理

Executive Industry Relevance

This protocol enables the production of human-derived cardiac extracellular matrix hydrogels and microparticles, providing a tissue-specific microenvironment for studying cell-matrix interactions in cardiac regeneration research. By preserving key biomolecules such as collagen, elastin, and glycosaminoglycans while removing cellular material, the method supports physiologically relevant in vitro and in vivo models. This approach addresses the lack of tissue-specific biological activity in commercial ECM products, offering a scalable source for mechanistic de-risking in cardiac therapeutic development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of cardiac extracellular matrix effects on pluripotent stem cell differentiation toward cardiomyocyte-like phenotypes.
• Operational Value: Provides a consistent, human-derived matrix substrate for functional target validation in cardiac pathways.

Screening & Assay Development

• Scientific Value: Generates standardized cardiac ECM microparticles and hydrogels suitable for high-throughput cell-based assays under ischemic conditions.
• Operational Value: Supports reproducible preparation of bioactive matrices for assessing compound effects on cell viability and metabolic activity.

Translational & Preclinical Research

• Scientific Value: Offers a disease-relevant system to evaluate matrix-mediated survival cues in models of myocardial infarction.
• Operational Value: Facilitates continuity from discovery to preclinical validation by providing implantable hydrogel formats with preserved bioactivity.

Pipeline & Workflow Integration

The method fits within the discovery continuum, supporting early target validation through matrix-dependent phenotypic screening and enabling translational progression via preclinical testing of ECM-based therapeutics.

• Discovery Biology: Supports hypothesis testing on how cardiac extracellular matrix influences stem cell fate and cell survival in ischemic environments.
• Screening: Delivers quantitative outputs such as metabolic activity and viability metrics for evaluating cellular responses to matrix cues.
• Analytics: Enables measurement of ECM composition (collagen, elastin, glycosaminoglycans) and DNA removal efficiency to assess matrix quality.
• Translational Research: Connects to preclinical work by providing implantable hydrogels that retain bioactive properties for regenerative applications.
• Enterprise Reuse: Establishes a scalable, standardized process for generating patient-relevant cardiac ECM materials across multiple projects.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence by providing a human cardiac matrix model that reduces mechanistic ambiguity in target validation.
• Operational Value: Ensures reproducibility through standardized decellularization, pulverization, and hydrogel reassembly steps.
• Strategic Value: Improves go/no-go decisions by enabling early assessment of matrix-dependent cellular responses in disease-relevant contexts.
• Portfolio Impact: Supports risk-adjusted advancement of cardiac regenerative candidates by validating microenvironmental effects prior to costly in vivo studies.

Implementation Considerations

• Requires expertise in tissue handling, decellularization, and hydrogel preparation.
• Dependent on access to sterile laboratory equipment including cryostat, lyophilizer, and milling apparatus.
• Necessitates standardized protocols for tissue sourcing, washing, and pepsin digestion to ensure batch consistency.
• Involves adaptation considerations when applying the matrix to different cardiac cell types or species.
• Limited by the availability of human cardiac tissue and the need for aseptic processing to prevent contamination.

Biopharma FAQs